- Home
- FWRG vs ZYME Comparison
FWRG vs ZYME Comparison
Compare FWRG & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWRG
- ZYME
- Stock Information
- Founded
- FWRG 1983
- ZYME 2003
- Country
- FWRG United States
- ZYME United States
- Employees
- FWRG N/A
- ZYME N/A
- Industry
- FWRG Restaurants
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- FWRG Consumer Discretionary
- ZYME Health Care
- Exchange
- FWRG Nasdaq
- ZYME Nasdaq
- Market Cap
- FWRG 970.4M
- ZYME 968.5M
- IPO Year
- FWRG 2021
- ZYME 2017
- Fundamental
- Price
- FWRG $16.49
- ZYME $16.49
- Analyst Decision
- FWRG Strong Buy
- ZYME Buy
- Analyst Count
- FWRG 10
- ZYME 7
- Target Price
- FWRG $22.20
- ZYME $20.00
- AVG Volume (30 Days)
- FWRG 1.1M
- ZYME 469.1K
- Earning Date
- FWRG 11-06-2025
- ZYME 10-30-2025
- Dividend Yield
- FWRG N/A
- ZYME N/A
- EPS Growth
- FWRG N/A
- ZYME N/A
- EPS
- FWRG 0.06
- ZYME N/A
- Revenue
- FWRG $1,105,027,000.00
- ZYME $122,867,000.00
- Revenue This Year
- FWRG $22.16
- ZYME $107.76
- Revenue Next Year
- FWRG $16.20
- ZYME $2.35
- P/E Ratio
- FWRG $279.13
- ZYME N/A
- Revenue Growth
- FWRG 14.53
- ZYME 95.94
- 52 Week Low
- FWRG $12.90
- ZYME $9.03
- 52 Week High
- FWRG $22.71
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- FWRG 35.03
- ZYME 68.82
- Support Level
- FWRG $16.98
- ZYME $15.79
- Resistance Level
- FWRG $17.83
- ZYME $16.37
- Average True Range (ATR)
- FWRG 0.60
- ZYME 0.70
- MACD
- FWRG -0.25
- ZYME 0.09
- Stochastic Oscillator
- FWRG 6.34
- ZYME 96.49
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.